Data Sheet (Cat.No.T11659)



Inogatran

Chemical Propert	ies
CAS No. :	155415-08-0
Formula:	C21H38N6O4
Molecular Weight:	438.56
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year

Biological Description

Description	Inogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of venous and arterial thrombotic diseases.
Targets(IC50)	Others
In vivo	Inogatran enhances vena caval blood circulation and diminishes the frequency of thrombotic occlusions in rat studies. Administered intravenously in a canine model of venous thrombosis at dosages of 0.075, 0.25, and 0.75 mg/kg, Inogatran (H-314-27) exhibits a dose-dependent augmentation in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT), indicative of its anticoagulant effects. This corresponds with a dose-related inhibition of thrombus formation, evidenced by extended time to occlusion (TTO) and reduced thrombus mass.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2802 mL	11.4009 mL	22.8019 mL
5 mM	0.456 mL	2.2802 mL	4.5604 mL
10 mM	0.228 mL	1.1401 mL	2.2802 mL
50 mM	0.0456 mL	0.228 mL	0.456 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ignasiak DP, et al. Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog. J Thromb Thrombolysis. 1998 Nov;6(3):199-206.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481